JP6645425B2 - 環状アミン誘導体及びその医薬用途 - Google Patents
環状アミン誘導体及びその医薬用途 Download PDFInfo
- Publication number
- JP6645425B2 JP6645425B2 JP2016520699A JP2016520699A JP6645425B2 JP 6645425 B2 JP6645425 B2 JP 6645425B2 JP 2016520699 A JP2016520699 A JP 2016520699A JP 2016520699 A JP2016520699 A JP 2016520699A JP 6645425 B2 JP6645425 B2 JP 6645425B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- imidazol
- reaction
- cyclic amine
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BERKYFKICZYNRP-UHFFFAOYSA-N CC(C)[n]1c(CCC(N(CCC2)CC2N(C)C)=O)ncc1 Chemical compound CC(C)[n]1c(CCC(N(CCC2)CC2N(C)C)=O)ncc1 BERKYFKICZYNRP-UHFFFAOYSA-N 0.000 description 1
- CGLYLGHRBZZCJA-UHFFFAOYSA-N C[n]1c(CCC(O)=O)ncc1 Chemical compound C[n]1c(CCC(O)=O)ncc1 CGLYLGHRBZZCJA-UHFFFAOYSA-N 0.000 description 1
- HDUFCQPRNLFRPA-UHFFFAOYSA-N O=Cc1ncc[n]1CC(F)(F)F Chemical compound O=Cc1ncc[n]1CC(F)(F)F HDUFCQPRNLFRPA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
一般式(I)で示される環状アミン誘導体(以下、環状アミン誘導体(I)と略す;その他の一般式で示される誘導体についても同様に略す。)は、例えば、塩基存在下又は非存在下、3−ジメチルアミノ環状アミン誘導体(II)とカルボン酸誘導体(III)とを縮合剤を用いて縮合反応することにより得られる。
環状アミン誘導体(I)の薬理学的に許容される塩は、例えば、環状アミン誘導体(I)と酸とを混合することによる塩化反応により得られる。
(工程1)
3−ジメチルアミノ環状アミン誘導体(V)は、ケト環状アミン誘導体(IV)とジメチルアミンとの還元的アミノ化反応により得られる。
3−ジメチルアミノ環状アミン誘導体(V)は、3−アミノ環状アミン誘導体(VI)とホルムアルデヒドとの還元的アルキル化反応により得られる。
3−ジメチルアミノ環状アミン誘導体(II)は、3−ジメチルアミノ環状アミン誘導体(V)の脱保護により得られる。
(工程4)
2−ホルミルイミダゾール誘導体(VIII)は、2−ホルミルイミダゾール誘導体(VII)の塩基による脱プロトン化後にアルキル化試薬(LI)を作用させるアルキル化反応により得られる。
2−ホルミルイミダゾール誘導体(VIII)は、アルコール誘導体(IX)の酸化反応により得られる。
アクリル酸エステル誘導体(X)は、2−ホルミルイミダゾール誘導体(VIII)のオレフィン化反応により得られる。
エステル誘導体(XI)は、アクリル酸エステル誘導体(X)に対し、水素雰囲気下で遷移金属触媒を用いる還元反応により得られる。
カルボン酸誘導体(III)は、エステル誘導体(XI)の加水分解反応により得られる。
1H-NMR (400 MHz, CDCl3) δ: 1.48 (3H, d, J=6.4 Hz), 1.48 (3H, d, J=6.4 Hz), 5.48 (1H, quint, J=6.4 Hz), 7.30 (1H, s), 7.33 (1H, s), 9.83 (1H, s).
ESI-MS: m/z= 139 (M+H)+.
1H-NMR (400 MHz, DMSO) δ: 3.21 (3H, s), 3.61 (2H, d, J=5.2 Hz), 4.53 (2H, d, J=5.2 Hz), 7.27 (1H, s), 7.62 (1H, s), 9.69 (1H, s).
ESI-MS: m/z= 155 (M+H)+.
1H−NMR(400 MHz, CDCl3) δ:5.16 (2H, q, J=8.0 Hz), 7.25 (1H, brs), 7.38 (1H, brs), 9.83-9.85 (1H, m).
ESI-MS: m/z= 179 (M+H)+.
1H−NMR(400 MHz, CDCl3) δ: 3.97 (3H, s), 7.24 (1H, s), 9.70 (1H, s).
ESI-MS: m/z= 145 (M+H)+.
1H−NMR(400 MHz, CDCl3) δ: 3.76 (3H, s), 3.81 (3H, s), 6.82 (1H, d, J=15.6 Hz), 6.98 (1H, brs), 7.16 (1H, brs), 7.53 (1H, d, J=15.6Hz).
ESI-MS: m/z= 167 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 1.50 (3H, d, J=6.4 Hz), 1.50 (3H, d, J=6.4 Hz), 3.81 (3H, s), 4.62 (1H, quint, J=6.4 Hz), 6.87 (1H, d, J=15.6 Hz), 7.10 (1H, brs), 7.18 (1H, brs), 7.56 (1H, d, J=15.6 Hz).
ESI-MS: m/z= 195 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 3.82 (3H, s), 4.56-4.64 (2H, m), 6.93 (1H, d, J=15.2 Hz), 7.10 (1H, brs), 7.24 (1H, brs), 7.44 (1H, d, J=15.2 Hz).
ESI-MS: m/z= 235 (M+H)+.
1H−NMR(400 MHz, CDCl3) δ: 1.32 (3H, t, J=7.2 Hz), 3.32 (3H, s), 3.63 (2H, t, J=5.2 Hz), 4.20 (2H, t, J=5.2 Hz), 4.26 (2H, q, J=7.2 Hz), 6.84 (1H, d, J=15.4 Hz), 7.08 (1H, brs), 7.16 (1H, brs), 7.52 (1H, d, J=15.4 Hz).
ESI-MS: m/z= 225 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 3.67-3.69 (3H, m), 3.80-3.82 (3H, m), 6.78-6.85 (1H, m), 7.08-7.10 (1H, m), 7.44-7.50 (1H, m).
ESI-MS: m/z= 201 (M+H)+.
1H−NMR(400 MHz, CDCl3) δ: 2.84-2.96 (4H, m), 3.53 (3H, s), 3.70 (3H, s), 6.84 (1H, s).
ESI-MS: m/z= 203 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 2.16(6H, s), 2.62-2.68(2H, m), 2.92-2.98(2H, m), 3.02-3.09(1H, m), 3.60(3H, m), 3.78-3.85(1H, m), 3.93-4.02(2H, m), 4.11-4.17(1H, m), 6.78(1H, d, J=1.2Hz), 6.91(1H, d, J=1.2Hz).
ESI-MS: m/z= 237 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.34-1.44(2H, m), 1.92-2.24(3H, m), 2.30(6H, s), 2.40-2.57(1H, m), 2.78-2.98(5H, m), 3.60(3H, s), 3.79-4.05(1H, m), 4.44-4.67(1H, m), 6.75-6.78(1H, m), 6.88-6.90(1H, m).
ESI-MS: m/z= 265 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.34-1.44(2H, m), 1.92-2.24(3H, m), 2.30(6H, s), 2.40-2.57(1H, m), 2.78-2.98(5H, m), 3.60(3H, s), 3.79-4.05(1H, m), 4.44-4.67(1H, m), 6.75-6.78(1H, m), 6.88-6.90(1H, m).
ESI-MS: m/z= 265 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.38-1.42(6H, m), 2.16(6H, s), 2.67-2.72(2H, m), 2.93-3.09(3H, m), 3.79-3.85(1H, m), 3.95-4.02(2H, m), 4.12-4.18(1H, m), 4.39-4.47(1H, m), 6.89-6.91(1H, m), 6.94-6.95(1H, m).
ESI-MS: m/z= 265 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.39-1.44(6H, m), 1.68-1.83(3H, m), 1.98-2.60(9H, m), 2.80-3.05(5H, m), 3.84-4.09(1H, m), 4.40-4.71(2H, m), 6.89-6.96(2H, m).
ESI-MS: m/z= 293 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 1.39-1.44(6H, m), 1.68-1.83(3H, m), 1.98-2.60(9H, m), 2.80-3.05(5H, m), 3.84-4.09(1H, m), 4.40-4.71(2H, m), 6.89-6.96(2H, m).
ESI-MS: m/z= 293 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:2.16(6H, s), 2.62-2.69(2H, m), 2.93-3.10(3H, m), 3.75-3.82(1H, m), 3.92-3.98(2H, m), 4.09-4.16(1H, m), 4.56-4.68(2H, m), 6.87-6.89(1H, m), 6.98-7.00(1H, m).
ESI-MS: m/z= 305 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 1.32-1.45(2H, m), 1.65-1.85(1H, m), 2.02-2.21(2H, m), 2.29-2.31(6H, m), 2.40-2.56(1H, m), 2.78-3.00(5H, m), 3.74-4.01(1H, m), 4.38-4.75(3H, m), 6.85-6.88(1H, m), 6.96-6.98(1H, m).
ESI-MS: m/z= 333 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ: 1.37-1.45(2H, m), 1.75-1.81(1H, m), 2.00-2.20(2H, m), 2.31-2.33(6H, m), 2.43-2.57(1H, m), 2.81-3.02(5H, m), 3.32 (3H, s), 3.59-3.62(2H, m), 3.84-4.11(3H, m), 4.49-4.69(1H, m), 6.89-6.93(2H, m).
ESI-MS: m/z= 309 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:2.17 (6H, s), 2.56-2.69 (2H, m), 2.87-3.00 (2H, m), 3.03-3.09 (3H, m), 3.53 (3H, s), 3.81 (1H, dd, J=9.9, 5.2 Hz), 3.95-4.01 (2H, m), 4.13-4.17 (1H, m), 6.83(1H, s).
ESI-MS: m/z= 271 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.30-1.48(2H, m), 1.68-1.84(1H, m), 1.92-2.22(2H, m), 2.28-2.31(6H, m), 2.40-2.58(1H, m), 2.77-3.00(5H, m), 3.51-3.54(3H, m), 3.75-4.02(1H, m), 4.42-4.64(1H, m), 6.80(1H, s).
ESI-MS: m/z= 299 (M+H)+.
1H-NMR (400 MHz, CDCl3) δ:1.30-1.48(2H, m), 1.68-1.84(1H, m), 1.92-2.22(2H, m), 2.28-2.31(6H, m), 2.40-2.58(1H, m), 2.77-3.00(5H, m), 3.51-3.54(3H, m), 3.75-4.02(1H, m), 4.42-4.64(1H, m), 6.80(1H, s).
ESI-MS: m/z= 299 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 2.74-2.80(2H, m), 2.89(6H, s), 3.21-3.28(2H, m), 3.82(3H, s), 4.12-4.28(2H, m), 4.32-4.50(2H, m), 4.57-4.66(1H, m), 7.28-7.36(2H, m).
ESI-MS: 1−(3−(ジメチルアミノ)アゼチジン−1−イル)−3−(1−メチル−1H−イミダゾール−2−イル)−プロパン−1−オンとして: m/z= 237 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.60-1.73(1H, m), 1.85-1.98(2H, m), 2.15-2.30(1H, m), 2.92-3.09(8H, m), 3.20-3.44(5H, m), 3.70-3.80(1H, m), 3.83(3H, s), 4.15-4.35(1H, m), 7.27-7.33(2H, m).
ESI-MS: (S)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−メチル−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 265 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.60-1.73(1H, m), 1.85-1.98(2H, m), 2.15-2.30(1H, m), 2.92-3.09(8H, m), 3.20-3.44(5H, m), 3.70-3.80(1H, m), 3.83(3H, s), 4.15-4.35(1H, m), 7.27-7.33(2H, m).
ESI-MS: (R)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−メチル−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 265 (M+H)+.
1H-NMR (400 MHz, D2O) δ:1.47-1.51(6H, m), 2.74-2.80(2H, m), 2.88(6H, s), 3.24-3.30(2H, m), 4.13-4.24(2H, m), 4.33-4.48(2H, m), 4.58-4.74(2H, m), 7.36-7.38(1H, m), 7.49-7.51(1H, m).
ESI-MS: 1−(3−(ジメチルアミノ)アゼチジン−1−イル)−3−(1−イソプロピル−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 265 (M+H)+.
1H-NMR (400 MHz, D2O) δ:1.48-1.70(8H, m), 1.86-1.98(2H, m), 2.12-2.28(1H, m), 2.89-3.12(8H, m), 3.24-3.45(5H, m), 3.71-3.82(1H, m), 4.14-4.36(1H, m), 7.35(1H, brs), 7.50(1H, brs).
ESI-MS: (S)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−イソプロピル−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 293 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.48-1.70(8H, m), 1.86-1.98(2H, m), 2.12-2.28(1H, m), 2.89-3.12(8H, m), 3.24-3.45(5H, m), 3.71-3.82(1H, m), 4.14-4.36(1H, m), 7.35(1H, brs), 7.50(1H, brs).
ESI-MS: (R)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−イソプロピル−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 293 (M+H)+.
1H-NMR (400 MHz, D2O) δ:2.77-2.84(2H, m), 2.89(6H, s), 3.27-3.33(2H, m), 4.13-4.26(2H, m), 4.32-4.47(2H, m), 4.57-4.64(1H, m), 5.08-5.16(2H, m), 7.42-7.46(1H, m), 7.51-7.55(1H, m).
ESI-MS: 1−(3−(ジメチルアミノ)アゼチジン−1−イル)−3−(1−(2,2,2−トリフルオロエチル)−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 305 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.42-1.70(1H, m), 1.83-1.94(2H, m), 2.12-2.27(1H, m), 2.87-2.94(6H, m), 3.04-3.14(2H, m), 3.23-3.42(5H, m), 3.70-3.78(1H, m), 4.12-4.32(1H, m), 5.10-5.18(2H, m), 7.43-7.45(1H, m), 7.52-7.54(1H, m).
ESI-MS: (R)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−(2,2,2−トリフルオロエチル)−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 333 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.44-1.68(1H, m), 1.74-1.93(2H, m), 2.16-2.24(1H, m), 2.89-2.93(6H, m), 3.00-3.08(2H, m), 3.23-3.41(8H, m), 3.70-3.76(1H, m), 3.82-3.85(2H, m), 4.14-4.30(1H, m), 4.36-4.38(2H, m), 7.33-7.34(1H, m), 7.40-7.42(1H, m).
ESI-MS: (R)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)−3−(1−(2−メトキシエチル)−1H−イミダゾール−2−イル)プロパン−1−オンとして: m/z= 309 (M+H)+.
1H-NMR (400 MHz, D2O) δ:2.78(2H, t, J=7.1 Hz), 2.92(6H, s), 3.26(2H, t, J= 7.1Hz), 3.77(3H, s), 4.17-4.28(2H, m), 4.37-4.41(1H, m), 4.45-4.48(1H, m), 4.61-4.66(1H, m), 7.44(1H, s).
ESI-MS: 3−(5−クロロ−1−メチル−1H−イミダゾール−2−イル)−1−(3−(ジメチルアミノ)アゼチジン−1−イル)プロパン−1−オンとして: m/z= 271 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.60-1.71(1H, m), 1.78-1.96(2H, m), 2.14-2.28(1H, m), 2.89-2.96(6H, m), 3.01-3.10(2H, m), 3.23-3.44(5H, m), 3.70-3.80(4H, m), 4.20-4.33(1H, m), 7.43(1H, s).
ESI-MS: (S)−3−(5−クロロ−1−メチル−1H−イミダゾール−2−イル)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)プロパン−1−オンとして: m/z= 299 (M+H)+.
1H-NMR (400 MHz, D2O) δ: 1.60-1.71(1H, m), 1.78-1.96(2H, m), 2.14-2.28(1H, m), 2.89-2.96(6H, m), 3.01-3.10(2H, m), 3.23-3.44(5H, m), 3.70-3.80(4H, m), 4.20-4.33(1H, m), 7.43(1H, s).
ESI-MS: (R)−3−(5−クロロ−1−メチル−1H−イミダゾール−2−イル)−1−(3−(ジメチルアミノ)ピペリジン−1−イル)プロパン−1−オンとして: m/z= 299 (M+H)+.
神経障害性疼痛を評価できるマウス坐骨神経部分結紮モデル(Seltzerモデル)を用い、環状アミン誘導体(I)又はその薬理学的に許容される塩の鎮痛作用を検討した。
マウス坐骨神経部分結紮モデルは、Seltzerらの方法(Malmbergら、Pain、1998年、第76巻、p.215−222)に従って作製した。
結果を図1〜12に示す。図において、縦軸はvon Frey試験の総スコア(平均値±標準誤差;図1〜12は、n=4〜6である。)を示し、数値が高いほど痛みが強いことを示す。横軸には被験化合物投与後の時間(hr)を示す。薬効評価は、測定時間毎の「坐骨神経部分結紮+蒸留水」群(図中の「坐骨神経部分結紮+蒸留水」)を対照として、多群の対応のないt検定(Dunnettによる補正)(図1〜3及び10〜12)又は対応のない2群のt検定(図4〜9)により統計処理を行った。図中の*印は、「坐骨神経部分結紮+蒸留水」群との比較で統計学的に有意である(p<0.05)ことを示す。
Claims (7)
- nは、1である、請求項1記載の環状アミン誘導体又はその薬理学的に許容される塩。
- R2は、水素原子又は塩素原子である、請求項1又は2記載の環状アミン誘導体又はその薬理学的に許容される塩。
- R1は、置換されていない炭素数1〜6の直鎖状、分岐鎖状又は環状の飽和炭化水素基である、請求項3記載の環状アミン誘導体又はその薬理学的に許容される塩。
- 請求項1〜4のいずれか一項記載の環状アミン誘導体又はその薬理学的に許容される塩を有効成分として含有する、医薬。
- 請求項1〜4のいずれか一項記載の環状アミン誘導体又はその薬理学的に許容される塩を有効成分として含有する、鎮痛薬。
- 請求項1〜4のいずれか一項記載の環状アミン誘導体又はその薬理学的に許容される塩を有効成分として含有する、神経障害性疼痛治療薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015061249 | 2015-03-24 | ||
JP2015061249 | 2015-03-24 | ||
PCT/JP2016/059293 WO2016152952A1 (ja) | 2015-03-24 | 2016-03-24 | 環状アミン誘導体及びその医薬用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016152952A1 JPWO2016152952A1 (ja) | 2018-01-11 |
JP6645425B2 true JP6645425B2 (ja) | 2020-02-14 |
Family
ID=56977381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016520699A Active JP6645425B2 (ja) | 2015-03-24 | 2016-03-24 | 環状アミン誘導体及びその医薬用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10253014B2 (ja) |
EP (1) | EP3275878B1 (ja) |
JP (1) | JP6645425B2 (ja) |
CN (2) | CN115124512A (ja) |
BR (1) | BR112017020203A2 (ja) |
CA (1) | CA2979326C (ja) |
ES (1) | ES2794560T3 (ja) |
MX (1) | MX2017011120A (ja) |
WO (1) | WO2016152952A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
DE10211770A1 (de) * | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPWO2006137465A1 (ja) * | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
TW201350119A (zh) * | 2012-03-29 | 2013-12-16 | Toray Industries | 環狀胺衍生物及其醫藥用途 |
TWI652264B (zh) | 2013-09-26 | 2019-03-01 | 東麗股份有限公司 | Cyclic amine derivatives and their medical uses |
EP3263565B1 (en) * | 2015-02-27 | 2019-06-26 | Toray Industries, Inc. | Cyclic amine derivative and pharmaceutical use thereof |
WO2016152955A1 (ja) * | 2015-03-24 | 2016-09-29 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
-
2016
- 2016-03-24 ES ES16768855T patent/ES2794560T3/es active Active
- 2016-03-24 CA CA2979326A patent/CA2979326C/en active Active
- 2016-03-24 JP JP2016520699A patent/JP6645425B2/ja active Active
- 2016-03-24 EP EP16768855.5A patent/EP3275878B1/en active Active
- 2016-03-24 US US15/560,365 patent/US10253014B2/en active Active
- 2016-03-24 MX MX2017011120A patent/MX2017011120A/es active IP Right Grant
- 2016-03-24 BR BR112017020203-4A patent/BR112017020203A2/ja not_active Application Discontinuation
- 2016-03-24 WO PCT/JP2016/059293 patent/WO2016152952A1/ja active Application Filing
- 2016-03-24 CN CN202210892020.9A patent/CN115124512A/zh active Pending
- 2016-03-24 CN CN201680011893.7A patent/CN107250129A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3275878A4 (en) | 2018-09-19 |
CN115124512A (zh) | 2022-09-30 |
ES2794560T3 (es) | 2020-11-18 |
EP3275878A1 (en) | 2018-01-31 |
CA2979326A1 (en) | 2016-09-29 |
WO2016152952A1 (ja) | 2016-09-29 |
JPWO2016152952A1 (ja) | 2018-01-11 |
CA2979326C (en) | 2023-05-16 |
US10253014B2 (en) | 2019-04-09 |
MX2017011120A (es) | 2017-11-28 |
US20180072701A1 (en) | 2018-03-15 |
CN107250129A (zh) | 2017-10-13 |
BR112017020203A2 (ja) | 2018-06-05 |
EP3275878B1 (en) | 2020-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6569671B2 (ja) | 環状アミン誘導体及びその医薬用途 | |
WO2013147160A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
JP6409573B2 (ja) | 環状アミン誘導体及びその医薬用途 | |
JP6645425B2 (ja) | 環状アミン誘導体及びその医薬用途 | |
JP6642422B2 (ja) | 環状アミン誘導体及びその医薬用途 | |
WO2021172488A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
JP2013500320A (ja) | 2−アミノ−2−フェニル−アルカノールの誘導体、その製造、及びこれを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190927 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191223 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 6645425 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |